A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer.

Irene TsungEdward GreenPhillip PalmbosZachery SloanZachery R ReichertUlka VaishampayanDavid C SmithMegan E V CaramSarah YentzStephanie Daignault-NewtonLaura HurleyCharles B NguyenShawna KraftAjjai Alva

Published in: The Journal of urology (2022)

The combination of nab-paclitaxel and pembrolizumab exhibited promising activity in advanced urothelial cancer and warrants further study in this population. After reduction in nab-paclitaxel starting dose, no unanticipated or unexpected toxicities emerged.

Keyphrases

advanced non small cell lung cancer
papillary thyroid
squamous cell
high grade
urinary tract
epidermal growth factor receptor
childhood cancer